PharmacoEconomics & Outcomes News 804, p30 - 2 Jun 2018 Screening for noncardia gastric cancer may be cost effective Endoscopic screening for noncardia gastric adenocarcinoma (NCGA) appears to be cost effective for ethnic groups in the US, according to findings of a study published in Gastroenterology. A Markov model was used to compare the cost effectiveness of a no screening (current standard) for noncardia gastric cancer, or one of two endoscopic screening stategies at the time of screening colonoscopy in 50-year-old non-Hispanic Whites, non-Hispanic Blacks, Hispanics or Asians: upper endoscopy (esophagogastroduodenoscopy [EGD]) with biopsies and continued surveillance in patients with intestinal metaplasia or severe pathology; or EGD with biopsies every two years. Cost effectiveness was assessed from a US healthcare perspective over a 30-year time horizon. The estimated incremental cost effectiveness ratio of EGD screening with surveillance if indicated, compared with no screening or biennial screening, was $122 428 per QALY gained in non-Hispanic Whites, $80 278 per QALY in non-Hispanic Blacks, $76 070 per QALY gained in Hispanics and $71 451 per QALY gained in Asians. EGD screening with surveillance if indicated was therefore cost effective at a willingness-to-pay threshold of $100 000 per QALY gained in non-Hispanic Blacks, Hispanics and Asians in the US, but not in non-Hispanic Whites. No screening was the most cost effective strategy in non-Hispanic Whites. "We found that targeted endoscopic screening (and surveillance if indicated) for NCGA among high-risk groups according to race and ethnicity might be a cost effective intervention in the US despite an overall low background prevalence of disease," said the authors. * 2015 US dollars Saumoy M, et al. Cost Effectiveness of Gastric Cancer Screening According to Race and Ethnicity. Gastroenterology : 17 May 2018. Available from: URL: https:/ /doi.org/10.1053/j.gastro.2018.05.026 803323155 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804
PharmacoEconomics & Outcomes News – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera